Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same author

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

Nature communications·2026
Same author

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

medRxiv : the preprint server for health sciences·2026
Same author

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.

Blood·2026
Same author

N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.

Molecular & cellular proteomics : MCP·2026
Same author

Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis.

JCO oncology advances·2026
Same journal

Non-canonical amino acid incorporation enables minimally disruptive labeling of stress granule and TDP-43 proteinopathy.

eLife·2026
Same journal

Analysis of dendritic input currents during place field dynamics.

eLife·2026
Same journal

TopoMetry systematically learns and evaluates the latent geometry of single-cell data.

eLife·2026
Same journal

Navigating the path: Advice to physician-scientists on choosing a clinical specialty.

eLife·2026
Same journal

Neural activity profiles reveal overlapping, intermingled subpopulations spanning area borders in mouse sensorimotor cortex.

eLife·2026
Same journal

The exquisite mechanics of a tsetse bite.

eLife·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

How does doxorubicin work?

Anand G Patel1, Scott H Kaufmann

  • 1is in the Department of Molecular Pharmacology and Experimental Therapeutics , Mayo Clinic , Rochester , United States.

Elife
|December 21, 2012
PubMed
Summary
This summary is machine-generated.

Researchers have uncovered a novel anti-cancer mechanism for doxorubicin. This involves the cleavage of the CREB3L1 transcription factor, offering new insights into doxorubicin

Keywords:
CREB3L1Humancancerceramidedoxorubicin

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Doxorubicin is a widely used chemotherapy agent.
  • The precise molecular mechanisms underlying its anti-tumour effects are not fully elucidated.
  • Understanding these mechanisms can lead to improved therapeutic strategies.

Purpose of the Study:

  • To investigate the molecular pathways responsible for doxorubicin's anti-cancer activity.
  • To identify key proteins and processes targeted by doxorubicin.

Main Methods:

  • Analysis of cellular responses to doxorubicin treatment.
  • Investigation of transcription factor activity, specifically CREB3L1.
  • Molecular assays to detect protein cleavage.

Main Results:

  • A novel mechanism of doxorubicin's action has been identified.
  • This mechanism involves the specific cleavage of the CREB3L1 transcription factor.
  • This cleavage is directly linked to the drug's anti-tumour effects.

Conclusions:

  • The cleavage of CREB3L1 represents a key molecular event in doxorubicin's anti-cancer efficacy.
  • Targeting this pathway could enhance doxorubicin's therapeutic potential.
  • Further research into CREB3L1 modulation may yield new cancer treatments.